S-(N-methylcarbamoyl)glutathione: metabolite of N-methylformamide [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
| ID Source | ID |
|---|---|
| PubMed CID | 115170 |
| SCHEMBL ID | 6726250 |
| MeSH ID | M0151047 |
| Synonym |
|---|
| s-(n-methylcarbamoyl)glutathione |
| snmcg |
| 38126-73-7 |
| (2s)-2-amino-5-[[(2r)-1-(carboxymethylamino)-3-(methylcarbamoylsulfanyl)-1-oxopropan-2-yl]amino]-5-oxopentanoic acid |
| fh7d8r2r6e , |
| glycine, l-gamma-glutamyl-s-((methylamino)carbonyl)-l-cysteinyl- |
| unii-fh7d8r2r6e |
| glycine, n-(n-l-gamma-glutamyl-s-((methylamino)carbonyl)-l-cysteinyl)- |
| l-gamma-glutamyl-s-((methylamino)carbonyl)-l-cysteinylglycine |
| SCHEMBL6726250 |
| DTXSID90191537 |
| s-(n-methylcarbamoyl) glutathione |
| glycine, n-(n-l-.gamma.-glutamyl-s-((methylamino)carbonyl)-l-cysteinyl)- |
| (2s)-2-amino-5-(((1r)-2-(carboxymethylamino)-1-(methylcarbamoylsulfanylmethyl)-2-oxo-ethyl)amino)-5-oxo-pentanoic acid |
| laromustine metabolite m4 |
| l-.gamma.-glutamyl-s-((methylamino)carbonyl)-l-cysteinylglycine |
| s-(n-methylcarbamoyl)gsh |
| glycine, l-.gamma.-glutamyl-s-((methylamino)carbonyl)-l-cysteinyl- |
| Excerpt | Reference | Relevance |
|---|---|---|
| " To study the mechanism of this toxicity, suspensions of mouse hepatocytes were tested as an in vitro model system suitable for the study of the relationship between (i) the toxic potential of formamides, (ii) their metabolism to N-alkylcarbamoylating species, and (iii) their ability to deplete hepatic glutathione pools." | ( Cytotoxicity and metabolism of the hepatotoxin N-methylformamide and related formamides in mouse hepatocytes. Gescher, A; Mráz, J; Shaw, AJ, 1988) | 0.27 |
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 3 (37.50) | 18.7374 |
| 1990's | 5 (62.50) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.26) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 9 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||